Related Experiment Video
Updated: Feb 8, 2026

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
Published on: February 8, 2017
Flavonoids Luteolin and Quercetin Inhibit RPS19 and contributes to metastasis of cancer cells through c-Myc reduction
Ku-Chung Chen1,2, Wen-Hsien Hsu1,3, Jhih-Yun Ho2
1Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Abstract:
Flavonoids luteolin and quercetin can inhibit growth and metastasis of cancer cells. In our previous report, luteolin and quercetin was shown to block Akt/mTOR/c-Myc signaling. Here, we found luteolin and quercetin reduced protein level and transactivation activity of RPS19 in A431-III cells, which is isolated from parental A431 (A431-P) cell line. Further investigation the inhibitory mechanism of luteolin and quercetin on RPS19, we found c-Myc binding sites on RPS19 promoter. The Akt inhibitor LY294002, mTOR inhibitor rapamycin and c-Myc inhibitor 10058-F4 significantly suppressed RPS19 expression and transactivation activities. Overexpression and knockdown of c-Myc in cancer cells show RPS19 expression was regulated by c-Myc. Furthermore, Knockdown and overexpression of RPS19 was used to analyze of the function of RPS19 in cancer cells. The epithelial-mesenchymal transition (EMT) markers and metastasis abilities of cancer cells were also regulated by RPS19. These data suggest that luteolin and quercetin might inhibit metastasis of cancer cells by blocking Akt/mTOR/c-Myc signaling pathway to suppress RPS19-activated EMT signaling.
Insights
Flavonoids luteolin and quercetin inhibit cancer cell metastasis by targeting RPS19. They block the Akt/mTOR/c-Myc pathway, suppressing RPS19-activated epithelial-mesenchymal transition (EMT) signaling.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Flavonoids luteolin and quercetin are known to inhibit cancer cell growth and metastasis.
- Previous studies demonstrated their ability to block the Akt/mTOR/c-Myc signaling pathway.
Purpose of the Study:
- To investigate the inhibitory mechanism of luteolin and quercetin on RPS19 expression and activity in cancer cells.
- To elucidate the role of RPS19 in cancer cell metastasis and its regulation by the Akt/mTOR/c-Myc pathway.
Main Methods:
- Investigated the effect of luteolin and quercetin on RPS19 protein levels and transactivation activity in A431-III cells.
- Analyzed c-Myc binding sites on the RPS19 promoter.
- Utilized specific inhibitors (LY294002, rapamycin, 10058-F4) and genetic manipulation (overexpression, knockdown) of c-Myc and RPS19.
- Assessed epithelial-mesenchymal transition (EMT) markers and cancer cell metastasis abilities.
Main Results:
- Luteolin and quercetin reduced RPS19 protein level and transactivation activity in A431-III cells.
- c-Myc was identified to bind to the RPS19 promoter, regulating its expression and activity.
- Inhibitors of Akt, mTOR, and c-Myc, as well as c-Myc manipulation, significantly affected RPS19 expression.
- RPS19 was found to regulate EMT markers and cancer cell metastasis.
Conclusions:
- Luteolin and quercetin inhibit cancer cell metastasis by suppressing RPS19.
- The mechanism involves blocking the Akt/mTOR/c-Myc signaling pathway, which in turn suppresses RPS19-activated EMT signaling.
Related Concept Videos
Feedback Inhibition
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Oxidation-Reduction Reactions
Binet's Contribution to Measures of Intelligence
Wechsler's Contribution to Measures of Intelligence
Enzyme Inhibition

